Status:
TERMINATED
A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Conditions:
Neurotoxicity Syndromes
Eligibility:
All Genders
2-21 years
Phase:
NA
Brief Summary
The purposes of this study are to find out whether dextromethorphan can prevent the short or long-term neurologic side effects of methotrexate, and whether dextromethorphan can improve symptoms of sho...
Detailed Description
We believe that we are beginning to understand the biological cause of the neurotoxicity that happens after treatment with methotrexate. Dextromethorphan, an ingredient in common cough medicines, may ...
Eligibility Criteria
Inclusion
- Newly diagnosed acute lymphocytic leukemia (ALL), non-Hodgkin's lymphoma (NHL) or OS. Patients will be separately stratified and randomized by disease.
- Patients with history of seizures are eligible but will be stratified separately.
Exclusion
- Patients taking monoamine oxidase inhibitors (MAOIs) will be excluded from the study, because of the risk of severe drug interactions.
- Pregnant or lactating women.
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00176553
Start Date
March 1 2003
End Date
May 1 2007
Last Update
December 11 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901